Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Tables)

v3.22.4
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Summary of Share-Based Compensation Expense The following table sets forth share-based compensation expense included in the consolidated statements of operations:
Years Ended December 31,
(in thousands)
2022 2021
Cost of revenue $ 63  $ 30 
Research and development 1,060  464 
Sales and marketing 809  351 
General and administrative 2,194  1,233 
  Share-based compensation expense $ 4,126  $ 2,078 
Share-based compensation expense by type of share-based award:
Years Ended December 31,
(in thousands)
2022 2021
Stock options $ 1,076  $ 686 
RSAs and RSUs 2,828  1,314 
ESPP 222  78 
  $ 4,126  $ 2,078 
Total unrecognized compensation expense by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):
December 31, 2022
Unrecognized Expense Remaining Weighted-Average Recognition Period (in years)
Stock options 1,306  1.87
RSAs and RSUs 5,649  2.13
Summary of Stock Option Activity
Stock option activity under all of the Company’s Plans as of and for the year ended December 31, 2022 is summarized below:
Stock Options Weighted-average
Exercise price
per share
Weighted-average Remaining Contractual Life (in years)
Intrinsic Value
(in thousands)(1)
Outstanding at December 31, 2021 1,350,473  $ 10.10 
Granted 147,723  $ 10.91 
Exercised (30,000) $ 2.45 
Forfeited or expired (69,910) $ 43.27 
Outstanding at December 31, 2022 1,398,286  $ 8.69  6.11 $ 5,328 
Exercisable at December 31, 2022 1,133,621  $ 8.12  5.47 $ 5,113 
Vested and expected to vest at December 31, 2022 1,398,286 $ 8.69  6.11 $ 5,328 
(1)    Intrinsic value is calculated as the estimated fair value of the Company’s stock at December 31, 2022 less the option exercise price of in-the-money options.
Summary of Non-vested Stock Options
A summary of the status of the Company’s non-vested stock options for the year ended December 31, 2022 is presented below:
Non-vested Stock Options Weighted - Average
Grant
Date Fair Value
Nonvested, December 31, 2021 291,220  $ 5.38 
Granted 147,723  $ 8.21 
Vested (169,987) $ 5.16 
Forfeited or expired (4,291) $ 10.33 
Nonvested, December 31, 2022 264,665  $ 7.19 
Summary of Fair Value Assumptions The fair value of each stock option is estimated on the date of grant using the Black-Scholes valuation model utilizing the following weighted average assumptions for options granted during the years ended December 31, 2022 and 2021:
Years Ended December 31,
2022 2021
Risk-free interest rate 3.07% 0.95%
Expected life (in years) 5.93 5.86
Estimated volatility 90.02% 57.20%
Expected dividends None None
Weighted-average grant date fair value $8.21 $9.48
The fair value of the purchase options under the Purchase Plan are estimated at the beginning of the purchase period using the Black-Scholes valuation model utilizing the following assumptions:
2022 2021
Risk-free interest rate
0.22% - 2.52%
0.05%
Expected life (in years) 0.5 0.5
Estimated volatility
61.29% - 78.23%
57.82%
Expected dividends None None
Fair value of purchase right $4.14 $5.78
Summary of Restricted Stock Awards Activity
RSA and RSU activity as of and for the year ended December 31, 2022 is summarized below:
Restricted Stock Award Weighted - Average
Grant
Date Fair Value
Outstanding, December 31, 2021 380,105  $ 10.41 
Granted 527,726  $ 10.97 
Vested (180,505) $ 13.09 
Forfeited or expired (29,791) $ 14.22 
Outstanding, December 31, 2022 697,535  $ 11.11 
Summary of Common Stock Warrant Activity
Common stock warrant activity for the year ended December 31, 2022 is as follows:
Shares Weighted - Average
Exercise
Price
Outstanding at December 31, 2021 668,907  $ 2.97 
Exercised (462,353) $ 2.20 
Terminated (170,000) $ 2.20 
Outstanding at December 31, 2022 36,554  $ 16.23 
Information regarding outstanding warrants at December 31, 2022 is as follows (contractual life expressed in years):
Exercise
Price
Number
Outstanding
Weighted-Average
Remaining
Contractual Life
Intrinsic Value
(in thousands)(1)
$16.23 36,554  0.46 — 
(1)    Intrinsic value is calculated as the estimated fair value of the Company’s stock at December 31, 2022 less the warrant exercise price of in-the-money warrants.